Abstract: The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoshell, wherein an active agent is loaded with the nanoshell.

Abstract: Modified-release multimicroparticulate pharmaceutical form capable of maintaining the modified release of the active principle in an alcoholic solution and of resisting attempts at misuse.

Abstract: Provided are methods for preventing and treating inflammation and organ injury after ischemia/reperfusion, and methods for treating lung injury, comprising administering a milk fat globule epidermal growth factor-factor VIII (MFG-E8) to a subject. Also provided are pharmaceutical compositions comprising MFG-E8 in dosage form for preventing and treating inflammation and organ injury after ischemia/reperfusion, and for treating lung injury, and methods of preparing a pharmaceutical composition for preventing and treating inflammation and organ injury after ischemia/reperfusion, and for treating lung injury, comprising formulating MFG-E8 in a pharmaceutical composition.

Abstract: This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

Abstract: The present invention pertains to a high drug load tablet comprising an active ingredient Compound I of formula or a pharmaceutically acceptable salt thereof in an amount from about 30% to 80% in weight of the active moiety based on the total weight of the tablet.

Abstract: It is an object of the present invention to provide a pest control composition capable of exerting a high effect on pests such as spider mites and aphids even at low concentration using a food/food additive with high safety to the human body and the environment. The present inventors have intensively studied to solve the above problem and found that, among polyglycerol fatty acid esters widely used as a food additive, a composition containing a polyglycerol fatty acid ester which has an HLB of 5 or less and is liquid at ordinary temperature and also a nonionic surfactant has a high effect on pests even at low concentration, and that the possibility for pests to develop resistance to the composition is extremely low, and the present invention has been completed.

Abstract: The present invention provides an implantable device having a biosoluble coating or a biosoluble body structure comprising a polyelectrolyte and a counterion and the methods of making and using the same.

Abstract: A pharmaceutical composition comprising 3 wt. % to 50 wt. % telmisartan dispersed in a dissolving matrix comprising: (a) a basic agent in a molar ratio of basic agent:telmisartan of 1:1 to 10:|1|; (b) about 1 wt. % to about 20 wt. % of a surfactant or emulsifier; (c) 25 wt. % to 70 wt. % of a water-soluble |diluent|; and (d) 0 wt. % to 20 wt. % of one or more additional excipients and/or |adjuvants|; wherein the sum of all components is 100%, methods of making such pharmaceutical compositions, and their use.

Abstract: A composition comprising coated particles of a salt of pyrithione selected from the group consisting of monovalent and polyvalent pyrithione salts, and combinations thereof, partially or fully coated with a lipophilic agent. The composition is characterized by enhanced anti-fungal and anti-dandruff efficacy in shampoos. Also disclosed is a personal care composition, preferably a shampoo, containing a topical carrier and coated particles of a salt of pyrithione selected from the group consisting of monovalent and polyvalent pyrithione salts, and combinations thereof, partially or fully coated with a lipophilic agent.

Abstract: In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to compounds comprising the structure: and at least one guanidinium residue, wherein m is zero or a positive integer. Also disclosed are methods of preparing the disclosed compounds. Also disclosed are methods of intracellular delivery comprising administering the disclosed compounds and compositions to a subject. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of one or more compounds or compositions of the invention and a pharmaceutically acceptable carrier. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A block copolymer comprising a methoxyethyl methacrylate (MOEMA) midblock is provided for forming a coating a medical device for controlled release of a bioactive agent.

Abstract: An antimicrobial composition comprises an anionic drug and an amine polymer comprising a first repeat unit of formula (2): wherein a? is an integer equal to 1 or 2, b? is an integer equal to 1 or 2, and each R? is an independent monovalent radical selected from the group consisting of hydrogen, methyl, ethyl, and combinations thereof. G? is a divalent linking group selected from the group consisting of a single bond and groups comprising at least one carbon. X? is a negatively charged counterion. The drug and the amine polymer are bound by noncovalent interactions.

Abstract: A method for immobilizing micro-particles, nano-particles or combinations thereof onto a surface is disclosed. The method includes distributing the micro-particles, nano-particles or combinations thereof onto the surface. The surface and the particles are exposed to thermal treatment, vapor treatment or combinations thereof, thereby adhering at least some of the micro-particles, nano-particles or combinations thereof to the surface. Materials including such immobilized micro-particles, nano-particles or combinations thereof are also disclosed herein.

Abstract: Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.

Abstract: The present application discloses biodegradable polymers, to porous and other materials comprising such polymers, and to various medical uses of such materials, including use as a scaffold for supporting cell adhesion or the in-growth for regeneration of tissue. The polymer is of the formula A-O—(CHR1CHR2O)n—B wherein A is a poly(lactide-co-glycolide) residue, the molar ratio of (i) lactide units [—CH(CH3)—COO—] and (ii) glycolide units [—CH2—COO—] in the poly(lactide-co-glycolide) residue being in the range of 80:20 to 10:90, B is either a poly(lactide-co-glycolide) residue or hydrogen, C1-6-alkyl or hydroxy protecting groups, one of R1 and R2 is hydrogen or methyl, and the other is hydrogen, n is 10-1000, the molar ratio of (iii) polyalkylene glycol units [—(CHR1CHR2O)—] to the combined amount of (i) lactide units and (ii) glycolide units in the poly(lactide-co-glycolide) residue(s) is at the most 14:86, and the molecular weight of the copolymer is at least 20,000 g/mol.

Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.

Abstract: Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

Abstract: The present invention relates to polymeric reagents and conjugates thereof, methods for synthesizing the polymeric reagents and conjugates, pharmaceutical compositions comprising the conjugates and methods of using the polymer conjugates including therapeutic methods where conjugates are administered to patients.

Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.